Alumis Inc. (ALMS) Stock

Alumis Inc. is dedicated to revolutionizing patient care by pioneering targeted therapies that replace broad immunosuppression with precise treatments. As a clinical-stage biopharmaceutical company, our primary focus is on advancing two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001 and A-005. ESK-001, a second-generation inhibitor, has shown promising therapeutic efficacy in our Phase 2 trials for moderate-to-severe plaque psoriasis (PsO). Currently, ESK-001 is undergoing further Phase 2 studies for systemic lupus erythematosus (SLE) and non-infectious uveitis, with anticipated results by the end of 2024 and 2026, respectively.

Based on encouraging Phase 2 outcomes in PsO, we plan to launch multiple Phase 3 trials of ESK-001 starting in the latter half of 2024. Meanwhile, our second candidate, A-005, is designed as a central nervous system (CNS) penetrant TYK2 inhibitor targeting neuroinflammatory and neurodegenerative disorders. We initiated the Phase 1 program for A-005 in healthy volunteers in April 2024 and expect initial findings by year-end 2024.

Alumis Inc. is driven by TYK2 genetic insights indicating protective effects against multiple sclerosis, underscoring our commitment to developing innovative treatments for debilitating conditions. With a strategic focus on precision medicine and rigorous clinical development, we aim to deliver transformative therapies that imprrove outcomes and quality of life for patients worldwide.